Vivos Therapeutics
VVOS
30 hedge funds and large institutions have $2.39M invested in Vivos Therapeutics in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.
40% more capital invested
Capital invested by funds: $1.71M → $2.39M (+$681K)
0% more funds holding
Funds holding: 30 → 30 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.17% less ownership
Funds ownership: 0.8% → 0.63% (-0.17%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$13.9K |
| 2 |
S
SignatureFD
Atlanta,
Georgia
|
+$5.36K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$4.85K |
| 4 |
VF
Virtu Financial
New York
|
+$1.89K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$402 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$68.8K |
| 2 |
Renaissance Technologies
New York
|
-$21.7K |
| 3 |
BlackRock
New York
|
-$18.1K |
| 4 |
Two Sigma Investments
New York
|
-$10.9K |
| 5 |
Millennium Management
New York
|
-$7K |
VVOS Hedge Fund Activity: Q2 2023 in Review
30 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q2 2023, worth a combined $2.39M — up 40% from $1.71M a quarter earlier.
Fund positioning in VVOS was balanced in Q2 2023: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 7 trimmed.
The largest buyer was LPL Financial, opening a new position worth an estimated $13.9K. The largest seller was Bard Associates, exiting entirely with an estimated $68.8K sold.
- 30 institutional investors held Vivos Therapeutics (VVOS) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $2.39M of Vivos Therapeutics stock for Q2 2023, up 40% quarter-over-quarter.
- 7 funds opened new Vivos Therapeutics positions in Q2 2023 and 7 closed out, a net change of 0 holders.
- The largest Vivos Therapeutics buyer in Q2 2023 was LPL Financial, an estimated $13.9K added.
- The largest Vivos Therapeutics seller in Q2 2023 was Bard Associates, an estimated $68.8K sold.
Based on aggregated 13F filings for Q2 2023.